1
|
Ray A, Du T, Wan X, Song Y, Pillai SC, Musa MA, Fang T, Moore J, Blank B, Du X, Chen X, Warne R, Sutimantanapi D, Lui F, Zavorotinskaya T, Colas C, Friedman L, Junttila MR, Chauhan D, Anderson KC. A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death. Blood Cancer J 2024; 14:58. [PMID: 38594241 PMCID: PMC11004003 DOI: 10.1038/s41408-024-01019-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 02/19/2024] [Accepted: 02/20/2024] [Indexed: 04/11/2024] Open
Abstract
CD73 is the key ectoenzyme involved in the generation of AMP-derived adenosine, which contributes to immunosuppression in the MM BM milieu. Blocking CD73 activity with a potent, selective, orally bioavailable CD73 inhibitor ORIC-533 decreases adenosine generation, overcomes immune suppression, and restores immune cell-mediated MM cell lysis. Based on these preclinical studies, a multi-center clinical trial of ORIC-533 has been initiated in patients with relapsed refractory MM (NCT05227144).
Collapse
Affiliation(s)
- Arghya Ray
- The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
| | - Ting Du
- The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Xueping Wan
- The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Yan Song
- The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Sindhu C Pillai
- The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Md Abu Musa
- The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Teng Fang
- The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Jared Moore
- ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA
| | - Brian Blank
- ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA
| | - Xiaohui Du
- ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA
| | - Xi Chen
- ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA
| | - Robert Warne
- ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA
| | | | - Fang Lui
- ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA
| | | | | | - Lori Friedman
- ORIC Pharmaceuticals, Inc., South San Francisco, CA, USA
| | | | - Dharminder Chauhan
- The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
| | - Kenneth C Anderson
- The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
2
|
McRee SK, Chen C, Colas C, Fang W, Kong W, Liu F, Long J, Moore J, Pankov A, Shore D, Tan J, Warne R, Vekariya R, Young A, Daemen A, Romero A, Junttila MR, Friedman LS, Edgar KA. Abstract 4998: Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-4998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Amplification and copy number gains of the 17q23 amplicon are common in breast cancer and neuroblastoma and have been associated with early relapse and poor prognosis (Ganesan et al 2012; Takita et al. 2017). A synthetic lethal interaction of PLK4 with 17q23 amplicon-driven overexpression of TRIM37 was discovered in these tumor types (Meitinger et al. 2020; Yeow et al. 2020). High levels of TRIM37 prevented acentrosomal spindle assembly and rendered cells mitotically vulnerable to inhibition of polo-like kinase 4 (PLK4), a serine/threonine protein kinase that controls centriole duplication. We have discovered that exquisitely selective small molecule inhibitors of PLK4, which are highly selective against the kinome including against the closely related aurora kinases and PLK1-3, display this synthetic lethal interaction with TRIM37, while less selective inhibitors do not. PLK4 protein levels are regulated through proteasomal degradation induced by PLK4 trans-autophosphorylation of the phosphodegron. PLK4 inhibition results in blocked trans-autophosphorylation leading to stabilization of PLK4, thus directly demonstrating target engagement in cells. Importantly, PLK4 protein stabilization correlated with cell viability for selective PLK4 inhibitors but not for less selective compounds, providing a quantifiable pharmacodynamic (PD) association with antitumor activity. Cell viability assessment in cancer cell lines revealed that highly selective PLK4 inhibitors showed greater potency in TRIM37 high cancer cell lines as compared to TRIM37 low cell lines. In contrast, less selective compounds, including from the clinical literature, did not display differential potency in TRIM37 high versus low cancer cell lines. Additionally, selective PLK4 inhibition induced significantly greater apoptosis in TRIM37 high versus low cancer cell lines as measured with a caspase 3/7 assay. We confirmed that only selective PLK4 inhibitors are synthetic lethal with TRIM37 amplification using an engineered cell line system of PLK4 G95L, in which the Leucine mutation blocks compound binding but allows the PLK4 enzyme to function. In cell viability assays, selective PLK4 inhibitors were potent in the parental G95 cells and lost activity in L95 cells, unlike less selective inhibitors whose potency did not depend on PLK4. Oral dosing of a selective PLK4 inhibitor resulted in tumor growth inhibition in TRIM37 high xenograft tumors with no body weight loss.
In summary, we have discovered that highly selective small molecule inhibitors of PLK4 confirm the potential of the synthetic lethal impact in treating tumors with high levels of TRIM37.
Citation Format: Siobhan K. McRee, Chelsea Chen, Christophe Colas, Wie Fang, Wayne Kong, Fang Liu, Jason Long, Jared Moore, Alex Pankov, Dan Shore, Joanne Tan, Robert Warne, Rakesh Vekariya, Amy Young, Anneleen Daemen, Anthony Romero, Melissa R. Junttila, Lori S. Friedman, Kyle A. Edgar. Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4998.
Collapse
Affiliation(s)
| | | | | | - Wie Fang
- 1ORIC Pharmaceuticals, South San Francisco, CA
| | - Wayne Kong
- 1ORIC Pharmaceuticals, South San Francisco, CA
| | - Fang Liu
- 1ORIC Pharmaceuticals, South San Francisco, CA
| | - Jason Long
- 1ORIC Pharmaceuticals, South San Francisco, CA
| | - Jared Moore
- 1ORIC Pharmaceuticals, South San Francisco, CA
| | - Alex Pankov
- 1ORIC Pharmaceuticals, South San Francisco, CA
| | - Dan Shore
- 1ORIC Pharmaceuticals, South San Francisco, CA
| | - Joanne Tan
- 1ORIC Pharmaceuticals, South San Francisco, CA
| | | | | | - Amy Young
- 1ORIC Pharmaceuticals, South San Francisco, CA
| | | | | | | | | | | |
Collapse
|
3
|
Aweda TA, Cheng SH, Lenhard SC, Sepp A, Skedzielewski T, Hsu CY, Marshall S, Haag H, Kehler J, Jagdale P, Peter A, Schmid MA, Gehman A, Doan M, Mayer AP, Gorycki P, Fanget M, Colas C, Smith B, Maier CC, Alsaid H. In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging 2023; 50:667-678. [PMID: 36305907 PMCID: PMC9614201 DOI: 10.1007/s00259-022-06012-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Accepted: 10/16/2022] [Indexed: 01/24/2023]
Abstract
PURPOSE Sotrovimab (VIR-7831), a human IgG1κ monoclonal antibody (mAb), binds to a conserved epitope on the SARS-CoV-2 spike protein receptor binding domain (RBD). The Fc region of VIR-7831 contains an LS modification to promote neonatal Fc receptor (FcRn)-mediated recycling and extend its serum half-life. Here, we aimed to evaluate the impact of the LS modification on tissue biodistribution, by comparing VIR-7831 to its non-LS-modified equivalent, VIR-7831-WT, in cynomolgus monkeys. METHODS 89Zr-based PET/CT imaging of VIR-7831 and VIR-7831-WT was performed up to 14 days post injection. All major organs were analyzed for absolute concentration as well as tissue:blood ratios, with the focus on the respiratory tract, and a physiologically based pharmacokinetics (PBPK) model was used to evaluate the tissue biodistribution kinetics. Radiomics features were also extracted from the PET images and SUV values. RESULTS SUVmean uptake in the pulmonary bronchi for 89Zr-VIR-7831 was statistically higher than for 89Zr-VIR-7831-WT at days 6 (3.43 ± 0.55 and 2.59 ± 0.38, respectively) and 10 (2.66 ± 0.32 and 2.15 ± 0.18, respectively), while the reverse was observed in the liver at days 6 (5.14 ± 0.80 and 8.63 ± 0.89, respectively), 10 (4.52 ± 0.59 and 7.73 ± 0.66, respectively), and 14 (4.95 ± 0.65 and 7.94 ± 0.54, respectively). Though the calculated terminal half-life was 21.3 ± 3.0 days for VIR-7831 and 16.5 ± 1.1 days for VIR-7831-WT, no consistent differences were observed in the tissue:blood ratios between the antibodies except in the liver. While the lung:blood SUVmean uptake ratio for both mAbs was 0.25 on day 3, the PBPK model predicted the total lung tissue and the interstitial space to serum ratio to be 0.31 and 0.55, respectively. Radiomics analysis showed VIR-7831 had mean-centralized PET SUV distribution in the lung and liver, indicating more uniform uptake than VIR-7831-WT. CONCLUSION The half-life extended VIR-7831 remained in circulation longer than VIR-7831-WT, consistent with enhanced FcRn binding, while the tissue:blood concentration ratios in most tissues for both drugs remained statistically indistinguishable throughout the course of the experiment. In the bronchiolar region, a higher concentration of 89Zr-VIR-7831 was detected. The data also allow unparalleled insight into tissue distribution and elimination kinetics of mAbs that can guide future biologic drug discovery efforts, while the residualizing nature of the 89Zr label sheds light on the sites of antibody catabolism.
Collapse
Affiliation(s)
- Tolulope A Aweda
- Bioimaging, GSK, 1250 S. Collegeville Rd, Collegeville, PA, 19426, USA
| | - Shih-Hsun Cheng
- Bioimaging, GSK, 1250 S. Collegeville Rd, Collegeville, PA, 19426, USA
| | - Stephen C Lenhard
- Bioimaging, GSK, 1250 S. Collegeville Rd, Collegeville, PA, 19426, USA
| | | | | | - Chih-Yang Hsu
- Bioimaging, GSK, 1250 S. Collegeville Rd, Collegeville, PA, 19426, USA
| | - Shelly Marshall
- Integrated Biological Platform Sciences, GSK, Collegeville, PA, USA
| | - Heather Haag
- Integrated Biological Platform Sciences, GSK, Collegeville, PA, USA
| | - Jonathan Kehler
- Bioanalysis, Immunogenicity & Biomarkers, GSK, Collegeville, PA, USA
| | | | - Alessia Peter
- mAb Engineering & Bioanalytics, Humabs BioMed SA, Vir Biotechnology, Inc, Bellinzona, Switzerland
| | - Michael A Schmid
- mAb Engineering & Bioanalytics, Humabs BioMed SA, Vir Biotechnology, Inc, Bellinzona, Switzerland
| | - Andrew Gehman
- Non-Clinical and Translational Statistics, GSK, Collegeville, PA, USA
| | - Minh Doan
- Bioimaging, GSK, 1250 S. Collegeville Rd, Collegeville, PA, 19426, USA
| | - Andrew P Mayer
- Bioanalysis, Immunogenicity & Biomarkers, GSK, Collegeville, PA, USA
| | | | - Marie Fanget
- Bioanalytical Department, Vir Biotechnology, Inc, San Francisco, CA, USA
| | | | - Brenda Smith
- Toxicology, Vir Biotechnology, Inc, San Francisco, CA, USA
| | | | - Hasan Alsaid
- Bioimaging, GSK, 1250 S. Collegeville Rd, Collegeville, PA, 19426, USA.
| |
Collapse
|
4
|
Baz M, Gondran-Teiller V, Bressac B, Cabaret O, Fievet A, Dimaria M, Goldbarg V, Colas C, Bonnet-Dupeyron MN, Tinat J, Lebrun M, Mari V, Limacher JM, Corsini C, Ginglinger E, Saurin JC, Brahimi A, Rouzier C, Giraud S, Schuster H, Hollebecque A, Boige V, Cauchin E, Malka D, Caron O, Rouleau E. The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients. Dig Dis Sci 2022; 68:1525-1528. [PMID: 36315333 DOI: 10.1007/s10620-022-07733-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 10/10/2022] [Indexed: 12/13/2022]
Abstract
Germline DNA alterations affecting homologous recombination pathway genes have been associated with pancreatic cancer (PC) risk. BRCA2 is the most studied gene and affects the management of PC patients and their families. Even though recent reports have suggested a similar role of germline ATM pathogenic variants (PV) in familial PC, there is still a disagreement between experts on how it could affect patient management given the lack of proper PC risk estimates. We retrospectively analyzed the germline data of 257 PC patients among whom nearly 50% were sporadic cases. We showed similar frequencies of BRCA2 (4.9%) and ATM (4.4%) PV or likely pathogenic variants, which were not related to familial history. Based on our findings and that of the literature, we suggest including ATM gene among the panel of genes analyzed in PC patients pending the publication of prospective studies.
Collapse
Affiliation(s)
- M Baz
- Département d'Oncogénétique, Hôpital Saint Louis, APHP, Paris, France.
| | | | - B Bressac
- Service de Génétique des Tumeurs, Gustave Roussy, Villejuif, France
| | - O Cabaret
- Service Oncogénétique, Gustave Roussy, Villejuif, France
| | - A Fievet
- Service Oncogénétique, Gustave Roussy, Villejuif, France
| | - M Dimaria
- Service Oncogénétique, Gustave Roussy, Villejuif, France
| | - V Goldbarg
- Service Oncogénétique, Gustave Roussy, Villejuif, France
| | - C Colas
- Département de Génétique (Department of Genetics), Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | | | - J Tinat
- Service de Génétique Médicale, Unité d'Oncogénétique, Centre Hospitalier, Universitaire de Bordeaux, Bordeaux, France
| | - M Lebrun
- CHU Saint Etienne, Genetic Service, Hôpital de Nord, Saint Etienne, France
| | - V Mari
- Centre Antoine Lacassagne, CLCC, Unité d'Oncogénétique, Nice, France
| | - J M Limacher
- Genetics Department, Hôpitaux Civils de Colmar, Colmar, France
| | - C Corsini
- Department of Cancer Genetics, CHU Montpellier, Univ Montpellier, Montpellier, France
| | - E Ginglinger
- CH de Mulhouse, Service de Génétique, Mulhouse, France
| | - J C Saurin
- Department of Endoscopy and Gastroenterology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | - A Brahimi
- Department of Clinical Genetics, CHU Lille, 59000, Lille, France
| | - C Rouzier
- Université Côte d'Azur, CHU de Nice, INSERM, CNRS, IRCAN, Nice, France
| | - S Giraud
- Service de Génétique Clinique, Centre Hospitalier Lyon-Sud, Lyon, France
| | - H Schuster
- Service d'Oncogénétique, CLCC Paul Strauss, Strasbourg, France
| | - A Hollebecque
- Département de Médecine Oncologique, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, Villejuif, France
| | - V Boige
- Département de Médecine Oncologique, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, Villejuif, France
| | - E Cauchin
- Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, Nantes, France
| | - D Malka
- Département de Médecine Oncologique, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, Villejuif, France
| | - O Caron
- Service Oncogénétique, Gustave Roussy, Villejuif, France
| | - E Rouleau
- Service de Génétique des Tumeurs, Gustave Roussy, Villejuif, France
| |
Collapse
|
5
|
Colas C, Grunewald T, Gobeaux F, Campos A, Burghammer M, Baroni A, Ferrand P, Chamard V, Chevallard C. Bio-inspired films of crystalline calcium carbonate: 2D patterning by surface-driven liquid–liquid phase separation and hybrid amorphous-to-crystal transformation. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322095651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
6
|
Baudot A, Barth N, Colas C, Garros M, Garcin A, Oriol M, Roche F, Chauvin F, Mottet N, Hupin D. The physical activity experience of prostate cancer patients: a multicentre peer motivation monitoring feasibility study. The Acti-Pair study. Pilot Feasibility Stud 2022; 8:12. [PMID: 35063040 PMCID: PMC8781045 DOI: 10.1186/s40814-022-00966-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Accepted: 01/05/2022] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND Although the benefits of physical activity (PA) on health are recognised, prostate cancer patients do not follow PA recommendations. The barriers to PA, whether physical, environmental or organisational, are known. Furthermore, even when such barriers are overcome, this achievement is not systematically accompanied by a change in lifestyle habits. The proposal of a programme enabling the integration of PA in the patient's everyday life represents a new challenge in the personalized management of cancer patients. Peer-mentoring interventions have demonstrated their effectiveness in increasing adherence to PA by patients. This study aimed (1) to assess the feasibility of a peer-mentoring intervention: the Acti-Pair program in a local context and (2) to assess the effectiveness of the intervention in this context. METHODS AND ANALYSIS A pre-post design pilot study will be used to evaluate feasibility, potential effectiveness and implementation outcomes overs in prostate cancer patients. We performed a mixed quantitative and qualitative prospective study to assess means and process indicators and the implementation of the Acti-Pair program. This study will be performed in cancer centres of Loire district and will be comprised of three successive stages (1) diagnosis of the target population, (2) recruitment and training of peers, and (3) implementation of this intervention in the Loire department. DISCUSSION This study will allow us to extend the peer-mentoring intervention to other contexts and assess the effectiveness of this intervention and its generalisability.
Collapse
Affiliation(s)
- A Baudot
- INSERM, U1059, SAINBIOSE, Université de Lyon, Université Jean-Monnet, Saint-Etienne, France
- Department of Clinical Investigation Centre, CIC 1408-INSERMClinical Investigation Centre, CIC 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France
- Clinical Research Unit Innovation and Pharmacology, University Hospital of Saint-Etienne, Saint-Etienne, France
- Presage Institute - Hygee Centre, Université de Lyon, Université Jean Monnet, Saint-Etienne, France
| | - N Barth
- INSERM, U1059, SAINBIOSE, Université de Lyon, Université Jean-Monnet, Saint-Etienne, France
- Chaire Santé des Ainés - Ingénierie de la prévention, Université de Lyon, Université Jean Monnet, Saint-Etienne, France
- Auvergne Rhône-Alpes (AURA) Gerontopole, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - C Colas
- INSERM, U1059, SAINBIOSE, Université de Lyon, Université Jean-Monnet, Saint-Etienne, France
- Department of Clinical and Exercise Physiology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - M Garros
- Sport-Health House, Departmental Olympic and Sports Committee of the Loire (42), Saint-Etienne, France
| | - A Garcin
- INSERM, U1059, SAINBIOSE, Université de Lyon, Université Jean-Monnet, Saint-Etienne, France
- Clinical Research Unit Innovation and Pharmacology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - M Oriol
- National Centre for Health Examination Prevention (CETAF), Saint Etienne, France
| | - F Roche
- INSERM, U1059, SAINBIOSE, Université de Lyon, Université Jean-Monnet, Saint-Etienne, France
- Chaire Santé des Ainés - Ingénierie de la prévention, Université de Lyon, Université Jean Monnet, Saint-Etienne, France
- Department of Clinical and Exercise Physiology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - F Chauvin
- Department of Clinical Investigation Centre, CIC 1408-INSERMClinical Investigation Centre, CIC 1408-INSERM, University Hospital of Saint-Etienne, Saint-Etienne, France
- Presage Institute - Hygee Centre, Université de Lyon, Université Jean Monnet, Saint-Etienne, France
| | - N Mottet
- Department of Urology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - D Hupin
- INSERM, U1059, SAINBIOSE, Université de Lyon, Université Jean-Monnet, Saint-Etienne, France.
- Chaire Santé des Ainés - Ingénierie de la prévention, Université de Lyon, Université Jean Monnet, Saint-Etienne, France.
- Department of Clinical and Exercise Physiology, University Hospital of Saint-Etienne, Saint-Etienne, France.
- Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
7
|
Villy MC, Masliah-Planchon J, Melaabi S, Trabelsi Grati O, Girard E, Bataillon G, Vincent-Salomon A, Le Gall J, Golmard L, Stoppa-Lyonnet D, Bieche I, Colas C. Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants. Gynecol Oncol Rep 2021; 37:100855. [PMID: 34541275 PMCID: PMC8435919 DOI: 10.1016/j.gore.2021.100855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 08/27/2021] [Accepted: 08/29/2021] [Indexed: 11/18/2022] Open
Abstract
Some gynecologic tumors harbor a POLE pathogenic variant, raising prognostic and therapeutic issues. Tumors harboring a POLE pathogenic variant exhibit multiple BRCA1/2 variants, reflecting the high tumor mutational burden. Tumor BRCA testing could be a way to detect tumors harboring a highly mutagenic POLE pathogenic variant.
Objective Tumors harboring a POLE pathogenic variant, associated with high tumor mutational burden, are good candidates for immunotherapy. However, POLE pathogenic variants are not currently screened in routine clinical practice. Can these tumors be identified by means of an already available test? Methods We describe seven tumors harboring a POLE pathogenic variant, among eight patients with tumors harboring multiple BRCA1/2 variants (from 4 to 20). All patients were managed at Institut Curie, Paris. Five patients were selected because of unexpected tumor BRCA testing results with multiple variants and another three patients were selected because of a POLE pathogenic variant detected by large tumor testing. We looked for other tumor variants by Next-Generation Sequencing in tumors harboring multiple BRCA1/2 variants, and for multiple BRCA1/2 variants in tumors harboring a POLE pathogenic variant. Results Four of the five tumors selected because of multiple BRCA1/2 variants exhibited a POLE pathogenic variant, and all three tumors selected for POLE pathogenic variants exhibited multiple BRCA1/2 variants. Conclusions Tumor BRCA testing could be a way to detect tumors harboring a highly mutagenic POLE pathogenic variant.
Collapse
Affiliation(s)
- M-C Villy
- Department of Genetics, Institut Curie, Paris, France
| | - J Masliah-Planchon
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - S Melaabi
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - O Trabelsi Grati
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - E Girard
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - G Bataillon
- Paris Sciences & Lettres Research University, Paris, France.,Department of Pathology, Institut Curie, Paris, France
| | - A Vincent-Salomon
- Paris Sciences & Lettres Research University, Paris, France.,Department of Pathology, Institut Curie, Paris, France
| | - J Le Gall
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - L Golmard
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - D Stoppa-Lyonnet
- Department of Genetics, Institut Curie, Paris, France.,Université de Paris, Paris, France.,Inserm U830, Institut Curie, Paris, France
| | - I Bieche
- Department of Genetics, Institut Curie, Paris, France.,Université de Paris, Paris, France
| | - C Colas
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France.,Inserm U830, Institut Curie, Paris, France
| |
Collapse
|
8
|
Suerink M, Wimmer K, Brugieres L, Colas C, Gallon R, Ripperger T, Benusiglio PR, Bleiker EMA, Ghorbanoghli Z, Goldberg Y, Hardwick JCH, Kloor M, le Mentec M, Muleris M, Pineda M, Ruiz-Ponte C, Vasen HFA. Report of the fifth meeting of the European Consortium 'Care for CMMRD' (C4CMMRD), Leiden, The Netherlands, July 6th 2019. Fam Cancer 2021; 20:67-73. [PMID: 32613597 PMCID: PMC7870763 DOI: 10.1007/s10689-020-00194-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Accepted: 06/17/2020] [Indexed: 01/08/2023]
Affiliation(s)
- M Suerink
- Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
| | - K Wimmer
- Division of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria
| | - L Brugieres
- Child and Adolescent Cancer Department, Gustave Roussy Cancer Campus, Villejuif, France
| | - C Colas
- Department of Genetics, Institut Curie, Université de Recherche Paris Sciences et Lettres, Paris, France
| | - R Gallon
- Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - T Ripperger
- Department of Human Genetics, Hannover Medical School, Hannover, Germany
| | - P R Benusiglio
- Sorbonne Université, Inserm, Unité Mixte de Recherche Scientifique 938, Equipe Instabilité Des Microsatellites et Cancer Centre de Recherche Saint-Antoine, CRSA, Paris, France
- Unité Fonctionnelle d'Oncogénétique, Département de Génétique et Institut Universitaire de Cancérologie, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Sorbonne Université, 75013, Paris, France
| | - E M A Bleiker
- Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands
- Division of Psychosocial Research and Epidemiology & Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Z Ghorbanoghli
- The Netherlands Foundation for the Detection of Hereditary Tumours, Leiden, The Netherlands
- Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands
| | - Y Goldberg
- Raphael Recanati Genetics Institute, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
| | - J C H Hardwick
- Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands
| | - M Kloor
- Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
- Clinical Cooperation Unit Applied Tumor Biology, DKFZ (German Cancer Research Center) Heidelberg, Heidelberg, Germany
| | - M le Mentec
- Department of Genetics, Institut Curie, Université de Recherche Paris Sciences et Lettres, Paris, France
| | - M Muleris
- Sorbonne Université, Inserm, Unité Mixte de Recherche Scientifique 938, Equipe Instabilité Des Microsatellites et Cancer Centre de Recherche Saint-Antoine, CRSA, Paris, France
| | - M Pineda
- Hereditary Cancer Program, Catalan Institute of Oncology, ONCOBELL Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Catalonia, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
| | - C Ruiz-Ponte
- Fundacion Publica Galega de Medicina Xenomica, SERGAS, Instituto de Investigacion Sanitaria de Santiago (IDIS), Grupo de Medicina Xenomica-USC, Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), 15706, Santiago de Compostela, Spain
| | - H F A Vasen
- Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands
| |
Collapse
|
9
|
Ohol YM, Sun MT, Cutler G, Leger PR, Hu DX, Biannic B, Rana P, Cho C, Jacobson S, Wong ST, Sanchez J, Shah N, Pookot D, Abraham B, Young K, Suthram S, Marshall LA, Bradford D, Kozon N, Han X, Okano A, Maung J, Colas C, Schwarz J, Wustrow D, Brockstedt DG, Kassner PD. Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo. Mol Cancer Ther 2020; 19:1970-1980. [DOI: 10.1158/1535-7163.mct-20-0184] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Revised: 06/18/2020] [Accepted: 07/30/2020] [Indexed: 11/16/2022]
|
10
|
Leger PR, Hu DX, Biannic B, Bui M, Han X, Karbarz E, Maung J, Okano A, Osipov M, Shibuya GM, Young K, Higgs C, Abraham B, Bradford D, Cho C, Colas C, Jacobson S, Ohol YM, Pookot D, Rana P, Sanchez J, Shah N, Sun M, Wong S, Brockstedt DG, Kassner PD, Schwarz JB, Wustrow DJ. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity. J Med Chem 2020; 63:5398-5420. [DOI: 10.1021/acs.jmedchem.0c00245] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Paul R. Leger
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Dennis X. Hu
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Berenger Biannic
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Minna Bui
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Xinping Han
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Emily Karbarz
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Jack Maung
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Akinori Okano
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Maksim Osipov
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Grant M. Shibuya
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Kyle Young
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Christopher Higgs
- Schrödinger, 120 West 45th Street, New York, New York 10036, United States
| | - Betty Abraham
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Delia Bradford
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Cynthia Cho
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Christophe Colas
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Scott Jacobson
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Yamini M. Ohol
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Deepa Pookot
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Payal Rana
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Jerick Sanchez
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Niket Shah
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Michael Sun
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Steve Wong
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Dirk G. Brockstedt
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Paul D. Kassner
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - Jacob B. Schwarz
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| | - David J. Wustrow
- RAPT Therapeutics, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States
| |
Collapse
|
11
|
Magassa S, Haddad M, El-Hafaia N, Colas C, Lafkihi S, Ramassamy R, Aboubacar M, De Bandt JP, Jegatheesan P. Citrulline, crosstalk hépatocytes-macrophages et stéatose hépatique non alcoolique. NUTR CLIN METAB 2020. [DOI: 10.1016/j.nupar.2020.02.401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Ohol YM, Sun M, Leger P, Hu D, Biannic B, Rana P, Cho C, Jacobson S, Wong S, Sanchez J, Han X, Young K, Okano A, Maung J, Cutler G, Shah N, Adusumilli L, Kaveri D, Talay O, Pookot D, Abraham B, Bradford D, Kozon N, Colas C, Kim A, Schwarz J, Wustrow D, Brockstedt D, Kassner P. Abstract 4441: Discovery of potent and selective inhibitors of USP7 with anti-tumor activity in vitro and in vivo. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-4441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
USP7 is a deubiquitinase that regulates the levels of multiple downstream targets with roles in cancer progression and immune response. Inhibitors of USP7 may thus decrease oncogene function, increase tumor suppressor function, enhance immune function and sensitize tumor cells to DNA damaging agents. We have discovered a novel chemical series that potently and selectively inhibits USP7 in biochemical and cellular assays. Our inhibitors reduce the viability of multiple p53-wild type cell lines, including several blood cancer and MYCN-amplified neuroblastoma cell lines, as well as a subset of p53-mutant tumor cell lines in vitro. Further, oral administration of our USP7 inhibitors inhibits MM.1S (multiple myeloma; p53-wild type) and H526 (small cell lung cancer; p53-mutant) tumor growth in vivo. Our work confirms that USP7 is a pharmacologically tractable target and future studies will aim to further understand the mechanism of action of USP7 inhibitors in p53-mutant cancers.
Citation Format: Yamini M. Ohol, Michael Sun, Paul Leger, Dennis Hu, Berenger Biannic, Payal Rana, Cynthia Cho, Scott Jacobson, Steve Wong, Jerick Sanchez, Xinping Han, Kyle Young, Akinori Okano, Jack Maung, Gene Cutler, Nick Shah, Lavanya Adusumilli, Deepika Kaveri, Oezcan Talay, Deepa Pookot, Betty Abraham, Delia Bradford, Nathan Kozon, Christophe Colas, Andrea Kim, Jacob Schwarz, David Wustrow, Dirk Brockstedt, Paul Kassner. Discovery of potent and selective inhibitors of USP7 with anti-tumor activity in vitro and in vivo [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4441.
Collapse
|
13
|
Jorapur A, Marshall L, Bradford D, Brovarney M, Chian D, Wadsworth A, Sanchez J, Jacobson S, Karbarz E, Robles O, Younai A, Ketcham J, Ng A, Tivitmahaisoon P, Pookot D, Marubayashi S, Kozon N, Colas C, Okal A, Cutler G, Wustrow D, Schwarz J, Talay O, Brockstedt D, Wong B. FLX193: A Potent, Selective CCR4 Antagonist for Allergic Disorders. The Journal of Immunology 2019. [DOI: 10.4049/jimmunol.202.supp.119.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Type 2 helper T cells (Th2)cells have been shown to express CCR4 receptor, and play a critical role in driving the pathogenesis of asthma and atopic dermatitis. FLX193 is a best-in-class, highly-potent and selective small molecule CCR4 antagonist under investigation for the treatment of allergic disorders. FLX193 blocked migration of CCR4+ Th2 cells (human and mouse) towards CCL17 and CCL22 in an in vitro chemotaxis assay. FLX193 is well-tolerated in animals at efficacious doses. In an Ovalbumin (OVA)-induced asthma model, FLX193 significantly reduced lymphocyte and eosinophil counts in the Bronchoalveolar lavage (BAL) fluid and showed a reduction of the effector Th2-relevant cytokines IL-5 and IL-13. FLX193 treatment also reduced the levels of CCL17 and CCL22 in the BAL fluid, indicating an overall reduction of inflammation. In addition, we used an atopic dermatitis mouse model to demonstrate that treatment with FLX193 decreased CCR4+ T-cell mediated inflammation. Hence, FLX193 shows promise in the treatment of atopic dermatitis.
Collapse
|
14
|
Tran M, Loirat D, Colas C, Bozec L, Laurence V, Lerebours F, Cabel L, Bidard FC, Stoppa-Lyonnet D, Vincent-Salomon A, Gauthier-Villars M, Lavigne M, De Pauw A. Abstract P1-09-07: Breast cancer characteristics and outcomes in patients with TP53 germline mutation. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-09-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Li-Fraumeni syndrome (LFS) resulting from monoallelic germline TP53 gene mutation is a rare hereditary cancer predisposition. Breast cancer (BC) is the most common cancer among women with TP53 germline mutation with a risk ranging from 49% to 85% by the age of 60 years old. Most of these cancers are early onset. Few patients' cases have been reported so far in the literature. Our aim was to describe the medical history of a cohort of LFS women diagnosed with BC recruited from a single institution. The characteristics combined were genetic alteration diagnosis, tumor characteristics, treatment, outcome, and LFS associated cancers.
Methods
We retrospectively identified breast cancer patients with TP53 germline mutation from the Institut Curie (Paris, France) database and described their cancer characteristics and medical history.
Results
From 1989 to 2015, 25 patients affected with BC (31 tumors) and TP53 germline mutation carrier were identified, with a median follow up of 6.5 years. Median age at BC diagnosis was 30.5 years. All patients were women. 33% had a previously identified TP53 mutation in their family. 70% of them had BC as their first cancer event. 60% of the patients presented with another LFS associated cancer or non-related cancers: osteosarcoma (22%), glioblastoma (18%), pulmonary carcinoma (13%), gastric linitis plastica (9%), malignant hemopathy (9%), soft tissue sarcoma (9%), adrenocortical carcinoma (4%), ovarian cystadenocarcinoma (4%), renal tumor (4%), choroid plexus carcinoma (4%).
92% of the breast tumors were ductal carcinoma (28% DCIS and 64% IDC), 7% were sarcoma (1 phyllodesarcoma, 1 pleiomorphic liposarcoma); there were no lobular carcinoma. Among the IDC, 50% were HER2 positive, 72% were hormone-receptor positive.
Most patients had a mastectomy (64%), and most of them received radiation (55%). However, when TP53 mutation had been identified prior to the treatment, none of the patients received radiotherapy (5 patients). Most patients received chemotherapy (70%) (37% in neoadjuvant setting, 33% in adjuvant setting, 25% for metastatic setting). 40% of the patients received hormone therapy (37% as adjuvant treatment, 7% for metastatic disease)
Most of the patients did not relapse from BC (75%). Overall, only 17% of the patients had metastatic BC. To date, 12 patients of our series have died (48%), 6 patients (24%) from other LFS-associated cancers and 4 patients from BC (16%).
Conclusion
To the best of our knowledge, this descriptive series is the largest study of tumor characteristics and medical history of LFS-women with BC, the most frequent cancer among women with TP53 germline mutation. It confirms the higher HER2 overexpression rate observed in LFS-patients BC, as suggested in the literature and showed a high rate of DCIS at initial presentation. Most of the patients developed other LFS-associated cancers. In depth molecular analysis of these BC will be performed in order to gain insight into their biological specificities and to adapt the therapeutic management of this poor prognosis syndrome.
Citation Format: Tran M, Loirat D, Colas C, Bozec L, Laurence V, Lerebours F, Cabel L, Bidard F-C, Stoppa-Lyonnet D, Vincent-Salomon A, Gauthier-Villars M, Lavigne M, De Pauw A. Breast cancer characteristics and outcomes in patients with TP53 germline mutation [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-09-07.
Collapse
Affiliation(s)
- M Tran
- Institut Curie, Paris, France
| | | | - C Colas
- Institut Curie, Paris, France
| | - L Bozec
- Institut Curie, Paris, France
| | | | | | - L Cabel
- Institut Curie, Paris, France
| | | | | | | | | | | | | |
Collapse
|
15
|
Fardjad S, Condamine L, Valser C, Colas C, Hardy B, Cosme S, Hareau E, Peyron E, Hutin E, Coulomb Y, Pauwels C, Brunet F, Zawistowicz D, Parejo-Margallo P, Gracies J. A functional restoration program (FRP) in chronical low back pain is efficient both in labourers and in sedentary workers. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Colamartino A, Bifsha P, Colas C, Nicoletti S, Guiot M, Boldici A, Li Y, Haddad E. A new immunotherapy approach against acute lymphoblastic leukemia by transducing hematopoietic stem cells with a car under regulation of cell specific promoter. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
17
|
Sablot D, Gaillard N, Colas C, Smadja P, Gely C, Dutray A, Bonnec JM, Jurici S, Farouil G, Ferraro-Allou A, Jantac M, Allou T, Pujol C, Olivier N, Laverdure A, Fadat B, Mas J, Dumitrana A, Garcia Y, Touzani H, Perucho P, Moulin T, Richard C, Heroum C, Bouly S, Sagnes-Raffy C, Heve D. Results of a 1-year quality-improvement process to reduce door-to-needle time in acute ischemic stroke with MRI screening. Rev Neurol (Paris) 2017; 173:47-54. [PMID: 28131535 DOI: 10.1016/j.neurol.2016.12.032] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Revised: 09/20/2016] [Accepted: 12/20/2016] [Indexed: 01/19/2023]
Abstract
OBJECTIVE To determine the effects of a 1-year quality-improvement (QI) process to reduce door-to-needle (DTN) time in a secondary general hospital in which multimodal MRI screening is used before tissue plasminogen activator (tPA) administration in patients with acute ischemic stroke (AIS). METHODS The QI process was initiated in January 2015. Patients who received intravenous (iv) tPA<4.5h after AIS onset between 26 February 2015 to 25 February 2016 (during implementation of the QI process; the "2015 cohort") were identified (n=130), and their demographic and clinical characteristics and timing metrics compared with those of patients treated by iv tPA in 2014 (the "2014 cohort", n=135). RESULTS Of the 130 patients in the 2015 cohort, 120 (92.3%) of them were screened by MRI. The median DTN time was significantly reduced by 30% (from 84min in 2014 to 59min; P<0.003), while the proportion of treated patients with a DTN time≤60min increased from 21% to 52% (P<0.0001). Demographic and baseline characteristics did not significantly differ between cohorts, and the improvement in DTN time was associated with better outcomes after discharge (patients with a 0-2 score on the modified rankin scale: 59% in the 2015 cohort vs 42.4% in the 2014 cohort; P<0.01). During the 1-year QI process, the median DTN time decreased by 15% (from 65min in the first trimester to 55min in the last trimester; P≤0.04) with a non-significant 1.5-fold increase in the proportion of treated patients with a DTN time≤60min (from 41% to 62%; P=0.09). CONCLUSION It is feasible to deliver tPA to patients with AIS within 60min in a general hospital, using MRI as the routine screening modality, making this QI process to reduce DTN time widely applicable to other secondary general hospitals.
Collapse
Affiliation(s)
- D Sablot
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France; Agence régionale de santé Languedoc-Roussillon et Midi-Pyrénées (ARS-LRMP), 28, parc club du Millénaire, 1025, avenue Henri-Becquerel, 34067 Montpellier, France.
| | - N Gaillard
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - C Colas
- Service d'accueil des urgences/SMUR 66, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - P Smadja
- Service de radiologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - C Gely
- Service d'accueil des urgences/SMUR 66, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - A Dutray
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - J-M Bonnec
- Service d'accueil des urgences/SMUR 66, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - S Jurici
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - G Farouil
- Service de radiologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - A Ferraro-Allou
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - M Jantac
- Service d'accueil des urgences/SMUR 66, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - T Allou
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - C Pujol
- Service d'accueil des urgences/SMUR 66, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - N Olivier
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - A Laverdure
- Service d'accueil des urgences/SMUR 66, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - B Fadat
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - J Mas
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - A Dumitrana
- Service de neurologie, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - Y Garcia
- Service d'accueil des urgences/SMUR 66, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - H Touzani
- Service de neurologie, centre hospitalier, boulevard Dr-Lacroix, 11100 Narbonne, France
| | - P Perucho
- Service de la qualité, centre hospitalier Saint-Jean, 20, avenue du Languedoc, BP 4052, 66046 Perpignan, France
| | - T Moulin
- Service de neurologie, CHU Minjoz, 3, boulevard A-Flemming, 25030 Besançon, France
| | - C Richard
- Agence régionale de santé Languedoc-Roussillon et Midi-Pyrénées (ARS-LRMP), 28, parc club du Millénaire, 1025, avenue Henri-Becquerel, 34067 Montpellier, France
| | - C Heroum
- Agence régionale de santé Languedoc-Roussillon et Midi-Pyrénées (ARS-LRMP), 28, parc club du Millénaire, 1025, avenue Henri-Becquerel, 34067 Montpellier, France
| | - S Bouly
- Agence régionale de santé Languedoc-Roussillon et Midi-Pyrénées (ARS-LRMP), 28, parc club du Millénaire, 1025, avenue Henri-Becquerel, 34067 Montpellier, France
| | - C Sagnes-Raffy
- Agence régionale de santé Languedoc-Roussillon et Midi-Pyrénées (ARS-LRMP), 28, parc club du Millénaire, 1025, avenue Henri-Becquerel, 34067 Montpellier, France
| | - D Heve
- Agence régionale de santé Languedoc-Roussillon et Midi-Pyrénées (ARS-LRMP), 28, parc club du Millénaire, 1025, avenue Henri-Becquerel, 34067 Montpellier, France
| |
Collapse
|
18
|
Caux F, Coulet F, Colas C, Laroche L, Longy M, Sevenet N. Maladie de Cowden et hypertrophie tissulaire unilatérales en rapport avec un mosaïcisme de type 1 du gène PTEN. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Colas C. Le patient expert, le patient ressource, le patient aidant ou tutoriel… Qui est-il ? Un nouveau professionnel de santé ? Quel rôle peut-il jouer ? Exercera-t-il un contre-pouvoir s’il possède « le » savoir ? ACTA ACUST UNITED AC 2015. [DOI: 10.1016/s1957-2557(15)30220-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, Coulet F, Cabaret O, Andreiuolo F, Charpy C, Sebille G, Wang Q, Lejeune S, Buisine MP, Leroux D, Couillault G, Leverger G, Fricker JP, Guimbaud R, Mathieu-Dramard M, Jedraszak G, Cohen-Hagenauer O, Guerrini-Rousseau L, Bourdeaut F, Grill J, Caron O, Baert-Dusermont S, Tinat J, Bougeard G, Frébourg T, Brugières L. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J Med Genet 2015; 52:770-8. [DOI: 10.1136/jmedgenet-2015-103299] [Citation(s) in RCA: 89] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Accepted: 08/01/2015] [Indexed: 12/20/2022]
|
21
|
Caux F, Coulet F, Colas C, Laroche L, Longy M, Sevenet N. Mosaïcisme de type 1 pour le gène PTEN responsable d’une hypertrophie tissulaire et d’une maladie de Cowden unilatérales. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.04.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Choi TA, Endsley AN, Bunin DI, Colas C, An DD, Morales-Rivera JA, Villalobos JA, Shinn WM, Dabbs JE, Chang PY, Abergel RJ. Biodistribution of the Multidentate Hydroxypyridinonate Ligand [14C]-3,4,3-LI(1,2-HOPO), a Potent Actinide Decorporation Agent. Drug Dev Res 2015; 76:107-22. [DOI: 10.1002/ddr.21246] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Accepted: 02/17/2015] [Indexed: 11/10/2022]
Affiliation(s)
- Taylor A. Choi
- Chemical Sciences Division; Lawrence Berkeley National Laboratory; Berkeley CA USA
| | | | | | | | - Dahlia D. An
- Chemical Sciences Division; Lawrence Berkeley National Laboratory; Berkeley CA USA
| | | | | | | | - Jack E. Dabbs
- Biosciences Division; SRI International; Menlo Park CA USA
| | - Polly Y. Chang
- Biosciences Division; SRI International; Menlo Park CA USA
| | - Rebecca J. Abergel
- Chemical Sciences Division; Lawrence Berkeley National Laboratory; Berkeley CA USA
| |
Collapse
|
23
|
Guyot A, Colas C, Coulet F, Cohen-Haguenauer O, Grossin M, Laroche L, Caux F. Sébacéome et cancers multiples : est-ce toujours un syndrome de Torre et Muir ? Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
24
|
Desrat S, Remeur C, Gény C, Rivière G, Colas C, Dumontet V, Birlirakis N, Iorga BI, Roussi F. From meiogynin A to the synthesis of dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins. Chem Commun (Camb) 2014; 50:8593-6. [DOI: 10.1039/c4cc01830c] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
25
|
Vasen HFA, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, Entz-Werle N, Goldberg Y, Ilencikova D, Kratz CP, Lavoine N, Loeffen J, Menko FH, Muleris M, Sebille G, Colas C, Burkhardt B, Brugieres L, Wimmer K. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D). J Med Genet 2014; 51:283-93. [PMID: 24556086 DOI: 10.1136/jmedgenet-2013-102238] [Citation(s) in RCA: 153] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Lynch syndrome (LS) is an autosomal dominant disorder caused by a defect in one of the DNA mismatch repair genes: MLH1, MSH2, MSH6 and PMS2. In the last 15 years, an increasing number of patients have been described with biallelic mismatch repair gene mutations causing a syndrome referred to as 'constitutional mismatch repair-deficiency' (CMMR-D). The spectrum of cancers observed in this syndrome differs from that found in LS, as about half develop brain tumours, around half develop digestive tract cancers and a third develop haematological malignancies. Brain tumours and haematological malignancies are mainly diagnosed in the first decade of life, and colorectal cancer (CRC) and small bowel cancer in the second and third decades of life. Surveillance for CRC in patients with LS is very effective. Therefore, an important question is whether surveillance for the most common CMMR-D-associated cancers will also be effective. Recently, a new European consortium was established with the aim of improving care for patients with CMMR-D. At a workshop of this group held in Paris in June 2013, one of the issues addressed was the development of surveillance guidelines. In 1968, criteria were proposed by WHO that should be met prior to the implementation of screening programmes. These criteria were used to assess surveillance in CMMR-D. The evaluation showed that surveillance for CRC is the only part of the programme that largely complies with the WHO criteria. The values of all other suggested screening protocols are unknown. In particular, it is questionable whether surveillance for haematological malignancies improves the already favourable outcome for patients with these tumours. Based on the available knowledge and the discussions at the workshop, the European consortium proposed a surveillance protocol. Prospective collection of all results of the surveillance is needed to evaluate the effectiveness of the programme.
Collapse
Affiliation(s)
- H F A Vasen
- Department of Gastroenterology & Hepatology, Leiden University Medical Centre, Leiden, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Coulet F, Fajac A, Colas C, Eyries M, Dion-Minière A, Rouzier R, Uzan S, Lefranc JP, Carbonnel M, Cornelis F, Cortez A, Soubrier F. GermlineRAD51Cmutations in ovarian cancer susceptibility. Clin Genet 2013; 83:332-6. [DOI: 10.1111/j.1399-0004.2012.01917.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2012] [Revised: 05/25/2012] [Accepted: 06/15/2012] [Indexed: 12/17/2022]
Affiliation(s)
- F Coulet
- Groupe hospitalier Pitié-Salpêtrière; Assistance Publique-Hopitaux de Paris, Université Pierre et Marie Curie, Département de Génétique; Paris; F-75651; France
| | - A Fajac
- Hôpital Tenon; Assistance Publique-Hopitaux de Paris, Laboratoire d'Histologie Biologie Tumorale; Paris; F-75651; France
| | - C Colas
- Groupe hospitalier Pitié-Salpêtrière; Assistance Publique-Hopitaux de Paris, Université Pierre et Marie Curie, Département de Génétique; Paris; F-75651; France
| | - M Eyries
- Groupe hospitalier Pitié-Salpêtrière; Assistance Publique-Hopitaux de Paris, Université Pierre et Marie Curie, Département de Génétique; Paris; F-75651; France
| | - A Dion-Minière
- Groupe hospitalier Pitié-Salpêtrière; Assistance Publique-Hopitaux de Paris, Université Pierre et Marie Curie, Département de Génétique; Paris; F-75651; France
| | - R Rouzier
- Hôpital Tenon; Assistance Publique-Hopitaux de Paris, Service de Chirurgie Gynecologique; Paris; F-75651; France
| | - S Uzan
- Hôpital Tenon; Assistance Publique-Hopitaux de Paris, Service de Chirurgie Gynecologique; Paris; F-75651; France
| | - J-P Lefranc
- Groupe hospitalier Pitié-Salpêtrière; Assistance Publique-Hopitaux de Paris, Université Pierre et Marie Curie, Service de Chirurgie Gynecologique; Paris; F-75651; France
| | - M Carbonnel
- Hôpital Jean Verdier; Assistance Publique-Hopitaux de Paris, Service de Chirurgie Gynecologique; Bondy; F-93143; France
| | - F Cornelis
- Hôpital Jean Verdier; Assistance Publique-Hopitaux de Paris, Service d'Anatomo-pathologie; Bondy; F-93143; France
| | - A Cortez
- Hôpital Tenon; Assistance Publique-Hopitaux de Paris, Service d'Anatomo-pathologie; Paris; F-75651; France
| | - F Soubrier
- Groupe hospitalier Pitié-Salpêtrière; Assistance Publique-Hopitaux de Paris, Université Pierre et Marie Curie, Département de Génétique; Paris; F-75651; France
| |
Collapse
|
27
|
Benusiglio P, Malka D, De Pauw A, Buecher B, Rouleau E, Colas C, Grandjouan S, Blayau M, Delaloge S, Caron O. Germline Mutations in CDH1 and the Hereditary Diffuse Gastric and Lobular Breast Cancer Syndrome. Ann Oncol 2012. [DOI: 10.1093/annonc/mds396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Nieuwenhuis MH, Kets CM, Murphy-Ryan M, Colas C, Möller P, Hes FJ, Hodgson SV, Olderode-Berends MJW, Aretz S, Heinimann K, Gomez Garcia EB, Douglas F, Spigelman A, Timshel S, Lindor NM, Vasen HFA. Is colorectal surveillance indicated in patients with PTEN mutations? Colorectal Dis 2012; 14:e562-6. [PMID: 22672595 DOI: 10.1111/j.1463-1318.2012.03121.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
AIM Patients with germline phosphatase and tensin homologue (PTEN) mutations develop hamartomatous lesions in several organs and are at increased risk of various malignancies. We assessed the lifetime risk of benign and malignant gastrointestinal lesions in patients with a proven PTEN mutation. METHOD Data on gender, mutation, dates of birth, last contact, and diagnosis, location and type of gastrointestinal lesions were collected from nine countries. The lifetime risk of gastrointestinal lesions was calculated by Kaplan-Meier methods. RESULTS A total of 156 patients (67 men, 43%) from 101 families with a PTEN mutation were included. Patients were born between 1928 and 2008. Benign gastrointestinal polyps were reported in 49 (31%) patients at a mean age of 38 years (range 18-62 years) and were most often hamartomas. Twenty-two (44%) patients had upper as well as lower gastrointestinal lesions, 14 (29%) had only colonic lesions and 13 (27%) had gastrointestinal lesions at unknown sites. The cumulative risk of developing benign gastrointestinal polyps was 70% at age 60. Four patients (two men) developed colorectal carcinoma at 53, 57, 59 and 62 years, respectively. The cumulative risk of developing colorectal carcinoma was 18% at age 60. Except for one carcinoid in the small intestine, no upper gastrointestinal cancers were observed. CONCLUSION Benign gastrointestinal lesions are common in PTEN mutation carriers, and a three- to four-fold increased lifetime risk of colorectal cancer compared with the general population may exist. Colorectal screening of patients with germline PTEN mutations is recommended, starting at age 40 years.
Collapse
Affiliation(s)
- M H Nieuwenhuis
- Netherlands Foundation for the Detection of Hereditary Tumors, Leiden, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Grandval P, Baert-Desurmont S, Bonnet F, Bronner M, Buisine MP, Colas C, Noguchi T, North MO, Rey JM, Tinat J, Toulas C, Olschwang S. Colon-specific phenotype in Lynch syndrome associated with EPCAM deletion. Clin Genet 2012; 82:97-9. [PMID: 22243433 DOI: 10.1111/j.1399-0004.2011.01826.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Caux F, Lévy A, Schischmanoff PO, Coulet F, Soubrier F, Parc Y, Laroche L, Colas C. Manifestations cutanées chez neuf patients porteurs de mutations bialléliques de MUTYH. Ann Dermatol Venereol 2011. [DOI: 10.1016/j.annder.2011.09.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Mongin C, Coulet F, Lefevre JH, Colas C, Svrcek M, Eyries M, Lahely Y, Fléjou JF, Soubrier F, Parc Y. Unexplained polyposis: a challenge for geneticists, pathologists and gastroenterologists. Clin Genet 2011; 81:38-46. [PMID: 21476993 DOI: 10.1111/j.1399-0004.2011.01676.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Two main colorectal polyposis syndromes have been described, familial adenomatous polyposis and MUTYH-associated polyposis syndromes. Some polyposis remains unexplained: 20% of adenomatous polyposis and serrated polyposis. The aim of this study was to evaluate in a cohort of patients with unexplained polyposis whether a genetic defect could be detected. Individuals presenting polyposis with more than 40 adenomas or more than 20 serrated polyps (hyperplastic, sessile serrated and mixed), without causative mutation identified, were included. Complementary explorations on APC or MUTYH were performed: search for APC mosaicism, splicing-affecting mutations, large genomic rearrangement of MUTYH. Four genes of Wnt pathway (AXIN2, PPP2R1B, WIF1, SFRP1) and two genes of transforming growth factor-β (TGF-β) pathway (SMAD4, BMPR1A) were screened for germline mutation. Twenty-five patients had an unexplained adenomatous polyposis (familial or sporadic). Five pathogenic mutations were found: four in APC gene (with one case of mosaicism) and one in BMPR1A gene. The exploration of APC mosaicism was better performed from adenoma DNA with high-resolution melting. The screening of the candidate genes did not find any causative mutation. Thirteen individuals had an unexplained serrated polyposis and a frameshift on SMAD4 gene was identified. All mutations were identified in familial cases of polyposis. After new pathological examination, both BMPR1A and SMAD4 cases were found to be associated with a juvenile polyposis while the polyposis was initially described as adenomatous or undetermined. In 17% (6/38) of the patients the causative mutation of the polyposis was identified. Genetic causes were heterogeneous. Sporadic polyposis patients must be considered as potential APC mosaicism. The histological classification of polyposis is strongly important in direct genetic exploration.
Collapse
Affiliation(s)
- C Mongin
- Oncogenetic and Molecular Angiogenetic Laboratory, Hospital Pitié-Salpêtrière AP-HP, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Lefevre JH, Colas C, Coulet F, Baert-Desurmont S, Mongin C, Tiret E, Frebourg T, Soubrier F, Parc Y. Frequent mutation in North African patients with MUTYH-associated polyposis. Clin Genet 2010; 80:389-93. [PMID: 21443744 DOI: 10.1111/j.1399-0004.2010.01528.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
MUTYH-associated polyposis (MAP) has been characterized as an autosomal recessive disease predisposing to a variable number of colorectal adenomas with a high risk of cancer. Numerous studies have indicated that two missense mutations (Y179C and G396D) account for about 80% of MUTYH allelic variants in Europeans. Ethnic and geographic differences in the mutation spectrum have been observed. The aim of this study was to report mutations in patients from North Africa, determine the incidence of the c.1227_1228dup mutation in our cohort of MUTYH patients and to evaluate the existence of a founder effect. Within a group of 36 families with MAP, 11 were shown to have a homozygous c.1227_1228dup mutation. These families came from Algeria (n = 5), Tunisia (n = 4), Morocco (n = 1) and Portugal (n = 1). Probands belonging to families of North African origin showed a significantly higher frequency of c.1227_1228dup (78.6% vs 4.5%, p < 0.0001). Haplotype analyses were performed using 10 microsatellite markers surrounding the MUTYH gene spanning a region of 4.4 cM. We identified a common haplotype of at least 1.3 cM in all families suggesting a founder effect for this mutation.
Collapse
Affiliation(s)
- J H Lefevre
- Department of Digestive Surgery, Hopital Saint-Antoine AP-HP, University Paris VI (Pierre and Marie Curie), Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Gracies JM, Bayle N, Vinti M, Alkandari S, Vu P, Loche CM, Colas C. Five-step clinical assessment in spastic paresis. Eur J Phys Rehabil Med 2010; 46:411-421. [PMID: 20927007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Among the three main factors of motor impairment that emerge in chronological order following a lesion to central motor pathways, the last two antagonize movement: 1) stretch-sensitive paresis, a reduction of agonist motor unit recruitment upon voluntary command, worsened by antagonist stretch; 2) soft tissue contracture, and 3) muscle overactivity. Types of muscle overactivity include 1) spasticity, an increase in the velocity-dependent response to muscle stretch, measured at rest; 2) spastic dystonia, i.e., chronic tonic muscle activity at rest, sensitive to stretch of the dystonic muscle and 3) spastic co-contraction, an inappropriate degree of antagonistic contraction during voluntary agonist command, sensitive to stretch of the co-contracting muscle. A five-step clinical assessment may closely parallel this phenomenology, in which the first four steps aim at quantifying the antagonistic potential of each muscle group. Step-1 measures passive range of motion, i.e., the angle of arrest upon slow stretch of the muscle group assessed (minimizing spastic dystonia), which provides insight on soft tissue length and extensibility. Step-2 measures the angle of catch or clonus upon fast passive stretch of the muscle group assessed, which provides insight on stretch reflex excitability. Step-3 measures the range of active motion against the muscle group assessed, a net result of agonist recruitment minus the combined resistance from passive soft tissue stiffness and spastic co-contraction in the muscle group assessed. Step-4 measures the maximal frequency of rapid alternating movements along the maximal active range of motion, evaluating Step-3 performance repeatability. Step-5 evaluates active function, using for example a walking test (10 m or 2 min) for lower limb and the Modified Frenchay Scale for upper limb assessment, and perceived function through patient global subjective assessment.
Collapse
Affiliation(s)
- Jean-Michel Gracies
- Physical and Rehabilitation Medicine Service, Unit of Neurore-education, Henri Mondor University Hospital, Créteil, France.
| | | | | | | | | | | | | |
Collapse
|
34
|
Beggs AD, Latchford AR, Vasen HFA, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RKS, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJW, Wijnen JT, Clark SK, Hodgson SV. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010; 59:975-86. [PMID: 20581245 DOI: 10.1136/gut.2009.198499] [Citation(s) in RCA: 414] [Impact Index Per Article: 29.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Peutz-Jeghers syndrome (PJS, MIM175200) is an autosomal dominant condition defined by the development of characteristic polyps throughout the gastrointestinal tract and mucocutaneous pigmentation. The majority of patients that meet the clinical diagnostic criteria have a causative mutation in the STK11 gene, which is located at 19p13.3. The cancer risks in this condition are substantial, particularly for breast and gastrointestinal cancer, although ascertainment and publication bias may have led to overestimates in some publications. Current surveillance protocols are controversial and not evidence-based, due to the relative rarity of the condition. Initially, endoscopies are more likely to be done to detect polyps that may be a risk for future intussusception or obstruction rather than cancers, but surveillance for the various cancers for which these patients are susceptible is an important part of their later management. This review assesses the current literature on the clinical features and management of the condition, genotype-phenotype studies, and suggested guidelines for surveillance and management of individuals with PJS. The proposed guidelines contained in this article have been produced as a consensus statement on behalf of a group of European experts who met in Mallorca in 2007 and who have produced guidelines on the clinical management of Lynch syndrome and familial adenomatous polyposis.
Collapse
Affiliation(s)
- A D Beggs
- Department of Clinical Genetics, St Georges, University of London, Cranmer Terrace, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Flejou J, Svrcek M, Parc Y, Lascols O, Colas C, Louvet C, Tiret E, Duval A, Hamelin R. The number of lymph nodes is influenced by the MSI phenotype in resected colorectal cancers (CRC): A study in a large monocentric series. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3607] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Ansquer Y, Santulli P, Colas C, Jamali M, Tournigand C, Duperray L, Duperray B, Jannet D, Carbonne B. [Lobular intra-epithelial neoplasia: atypical lobular hyperplasia and lobular carcinoma in situ]. ACTA ACUST UNITED AC 2010; 39:91-101. [PMID: 20116180 DOI: 10.1016/j.jgyn.2009.11.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2009] [Revised: 10/26/2009] [Accepted: 11/06/2009] [Indexed: 01/08/2023]
Abstract
OBJECTIVE To review main knowledge about lobular intra-epithelial neoplasia with special interest for daily practice management. MAIN RESULTS Intra-epithelial lobular neoplasias (ILN) are non invasive proliferations within the terminal ducto-lobular unit of monomorphic loosely cohesive small cells. A lack of expression of the E-cadherin adhesion molecule is often observed as in invasive lobular breast cancer. ILN are infrequent, however, a rise in incidence partly, due to the generalization of mammographic screening, is observed. Actually ILN are usually asymptomatic and diagnosed after breast biopsy for unspecified microcalcifications. ILN are associated with an increased risk of breast cancer that persists over 20 years after the initial diagnosis. The average risk is 4.2 % for the ipsilateral breast and 3,5 % for the controlateral breast. However, a great variability in the risk estimation is observed between the studies. There is no consensus on how to treat ILN. Surgical options have varied from biopsy to bilateral mastectomy. Current tendency is favouring lumpectomy.
Collapse
Affiliation(s)
- Y Ansquer
- Service de gynécologie-obstétrique, hôpital Saint-Antoine, Assistance publique-Hôpitaux de Paris, université Pierre-et-Marie-Curie-Paris VI, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Barber D, de la Torre F, Lombardero M, Antépara I, Colas C, Dávila I, Tabar AI, Vidal C, Villalba M, Salcedo G, Rodríguez R. Component-resolved diagnosis of pollen allergy based on skin testing with profilin, polcalcin and lipid transfer protein pan-allergens. Clin Exp Allergy 2009; 39:1764-73. [PMID: 19877313 DOI: 10.1111/j.1365-2222.2009.03351.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Allergy diagnosis needs to be improved in patients suffering from pollen polysensitization due to the existence of possible confounding factors in this type of patients. OBJECTIVE To evaluate new diagnostic strategies by comparing skin responses to pan-allergens and conventional allergenic extracts with specific IgE (sIgE) to purified allergen molecules. METHODS One thousand three hundred and twenty-nine pollen-allergic patients were diagnosed by a combination of an in vitro method with a panel of 13 purified allergens, including major allergens and pan-allergens, using a high-capacity screening technology (ADVIA-Centaur) and skin prick test (SPT) to pan-allergens and conventional extracts. RESULTS There was a high concordance (kappa index) between in vitro (sIgE to major allergens) and in vivo (SPT to conventional extracts) methods in patients who were not sensitized to pan-allergens, but SPT with conventional extracts failed to diagnose patients with sensitization to pan-allergens. In patients who were simultaneously sensitized to polcalcins and profilins, there was a duplication both in the number of sensitizations to major allergens and in the years of disease evolution. There was a statistical association between sensitization to profilins and/or lipid transfer proteins and food allergy (P<0.0001). CONCLUSION The novel diagnostic strategy has proven to be a valuable tool in daily clinical practice. Introduction of routine SPT to pan-allergens is a simple and feasible way of improving diagnostic efficacy. Patients sensitized to pan-allergens should be tested by an adequate panel of allergenic molecules in order to identify the allergens that are responsible for the allergic disease.
Collapse
Affiliation(s)
- D Barber
- Departamento de I+D, ALK-Abelló, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Sinilnikova OM, Antoniou AC, Simard J, Healey S, Léoné M, Sinnett D, Spurdle AB, Beesley J, Chen X, Greene MH, Loud JT, Lejbkowicz F, Rennert G, Dishon S, Andrulis IL, Domchek SM, Nathanson KL, Manoukian S, Radice P, Konstantopoulou I, Blanco I, Laborde AL, Durán M, Osorio A, Benitez J, Hamann U, Hogervorst FBL, van Os TAM, Gille HJP, Peock S, Cook M, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Brewer C, Hughes DJ, Coupier I, Giraud S, Coulet F, Colas C, Soubrier F, Rouleau E, Bièche I, Lidereau R, Demange L, Nogues C, Lynch HT, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Sutter C, Deissler H, Schaefer D, Froster UG, Aittomäki K, Nevanlinna H, McGuffog L, Easton DF, Chenevix-Trench G, Stoppa-Lyonnet D. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2009; 101:1456-60. [PMID: 19707196 PMCID: PMC2768437 DOI: 10.1038/sj.bjc.6605279] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background: The TP53 pathway, in which TP53 and its negative regulator MDM2 are the central elements, has an important role in carcinogenesis, particularly in BRCA1- and BRCA2-mediated carcinogenesis. A single nucleotide polymorphism (SNP) in the promoter region of MDM2 (309T>G, rs2279744) and a coding SNP of TP53 (Arg72Pro, rs1042522) have been shown to be of functional significance. Methods: To investigate whether these SNPs modify breast cancer risk for BRCA1 and BRCA2 mutation carriers, we pooled genotype data on the TP53 Arg72Pro SNP in 7011 mutation carriers and on the MDM2 309T>G SNP in 2222 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Data were analysed using a Cox proportional hazards model within a retrospective likelihood framework. Results: No association was found between these SNPs and breast cancer risk for BRCA1 (TP53: per-allele hazard ratio (HR)=1.01, 95% confidence interval (CI): 0.93–1.10, Ptrend=0.77; MDM2: HR=0.96, 95%CI: 0.84–1.09, Ptrend=0.54) or for BRCA2 mutation carriers (TP53: HR=0.99, 95%CI: 0.87–1.12, Ptrend=0.83; MDM2: HR=0.98, 95%CI: 0.80–1.21, Ptrend=0.88). We also evaluated the potential combined effects of both SNPs on breast cancer risk, however, none of their combined genotypes showed any evidence of association. Conclusion: There was no evidence that TP53 Arg72Pro or MDM2 309T>G, either singly or in combination, influence breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Collapse
Affiliation(s)
- O M Sinilnikova
- Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, Centre Léon Bérard, Lyon 69373, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Mouret-Fourme E, Andrieu N, Chompret A, Caron O, Gauthier-Villars M, Stoppa-Lyonnet D, Fricker J, Lasset C, Bonadona V, Berthet P, Faivre L, Luporsi E, Frénay M, Gladieff L, Guimbaud R, Gesta P, Sobol H, Huiart L, Eisinger F, Longy M, Dugast C, Colas C, Coupier I, Pujol P, Lortholary A, Vennin P, Adenis C, Nguyen TD, Delnatte C, Chevrier A, Rossi A, Limacher J, Caron O, Bignon Y, Demange L, Dreyfus H, Cohen-Haguenauer O, Venat-Bouvet L, Zattara-Cannoni H, Bonaïti C, Noguès C. Estimation du risque de cancer du sein dans une cohorte prospective de femmes porteuses d’une mutation sur les gènes BRCA : cohorte nationale GENEPSO. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.02.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
40
|
Valero A, Baró E, Sastre J, Navarro-Pulido AM, Izquierdo I, Martí-Guadaño E, Ferrer M, Dávila I, del Cuvillo A, Colas C, Antepara I, Alonso J, Mullol J. Reference values for facilitating the interpretation of the ESPRINT-15 questionnaire (Spanish version). J Investig Allergol Clin Immunol 2009; 19:396-403. [PMID: 19862940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Abstract
OBJECTIVE ESPRINT-15 is a specific, short-form instrument to measure health-related quality of life in adults suffering from allergic rhinitis. The aim of this study was to obtain reference values in order to improve its interpretability. METHODS ESPRINT-15 was administered to a representative sample of Spanish adults with allergic rhinitis. Means and percentiles were obtained, taking into account the kind of rhinitis (persistent/intermittent) and symptom severity (very mild/mild/moderate/severe). RESULTS A total of 2756 patients participated in the study. Mean (SD) scores were significantly lower (better) for men than for women (2.2 [1.4] vs 2.4 [1.4], P<.001, effect size [ES] is congruent to 0.15). Patients with intermittent rhinitis showed better scores than patients with persistent rhinitis (2.1 [1.4] vs. 2.5 [1.4], P<.001, ES is congruent to 0.21). Mean (SD) scores were higher (worse) when severity of symptoms increased, ranging from 0.9 (0.9) (very mild) to 3.7 (1.0) (severe) (ES is congruent to 1.0 between each consecutive group of symptom severity). CONCLUSIONS The magnitude of the differences found among groups of patients reinforces the usefulness of providing reference values stratified by gender, type of allergic rhinitis, and symptom severity. The percentiles obtained can be used in clinical practice to evaluate individual scores, and assign the patient to the corresponding reference group.
Collapse
Affiliation(s)
- A Valero
- Allergy Unit, Pneumology and Allergy Department, Hospital Clinic, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Colas C, Popot MA, Garcia P, Bonnaire Y, Bouchonnet S. Analysis of iridoids fromHarpagophytumand eleutherosides fromEleutherococcus senticosusin horse urine. Biomed Chromatogr 2008; 22:912-7. [DOI: 10.1002/bmc.1030] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
42
|
Svrcek M, Buhard O, Dumont S, Colas C, Coulet F, Cosnes J, Tiret E, Fléjou J, Duval A. Loss of MGMT expression as a pre-neoplastic event favoring the emergence of MSI colorectal cancers. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Vasen HFA, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Järvinen H, Mecklin JP, Møller P, Myrhøi T, Nagengast FM, Parc Y, Phillips R, Clark SK, de Leon MP, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJW, Wijnen J. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57:704-13. [PMID: 18194984 DOI: 10.1136/gut.2007.136127] [Citation(s) in RCA: 443] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Familial adenomatous polyposis (FAP) is a well-described inherited syndrome, which is responsible for <1% of all colorectal cancer (CRC) cases. The syndrome is characterised by the development of hundreds to thousands of adenomas in the colorectum. Almost all patients will develop CRC if they are not identified and treated at an early stage. The syndrome is inherited as an autosomal dominant trait and caused by mutations in the APC gene. Recently, a second gene has been identified that also gives rise to colonic adenomatous polyposis, although the phenotype is less severe than typical FAP. The gene is the MUTYH gene and the inheritance is autosomal recessive. In April 2006 and February 2007, a workshop was organised in Mallorca by European experts on hereditary gastrointestinal cancer aiming to establish guidelines for the clinical management of FAP and to initiate collaborative studies. Thirty-one experts from nine European countries participated in these workshops. Prior to the meeting, various participants examined the most important management issues according to the latest publications. A systematic literature search using Pubmed and reference lists of retrieved articles, and manual searches of relevant articles, was performed. During the workshop, all recommendations were discussed in detail. Because most of the studies that form the basis for the recommendations were descriptive and/or retrospective in nature, many of them were based on expert opinion. The guidelines described herein may be helpful in the appropriate management of FAP families. In order to improve the care of these families further, prospective controlled studies should be undertaken.
Collapse
Affiliation(s)
- H F A Vasen
- Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Rijnsburgerweg 10, 2333 AA Leiden, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Colas C, Garcia P, Popot MA, Bonnaire Y, Bouchonnet S. Optimization of Solid-Phase Extraction for the Liquid Chromatography--Mass Spectrometry Analysis of Harpagoside, 8-para-Coumaroyl Harpagide, and Harpagide in Equine Plasma and Urine. J Chromatogr Sci 2008; 46:174-83. [DOI: 10.1093/chromsci/46.2.174] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
45
|
Huang L, Colas C, Ortiz de Montellano PR. Oxidation of carboxylic acids by horseradish peroxidase results in prosthetic heme modification and inactivation. J Am Chem Soc 2005; 126:12865-73. [PMID: 15469283 DOI: 10.1021/ja046455w] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Hemoproteins are powerful oxidative catalysts. However, despite the diversity of functions known to be susceptible to oxidation by these catalysts, it is not known whether they can oxidize carboxylic acids to carboxylic radicals. We report here that incubation of horseradish peroxidase (HRP) at acidic pH with H(2)O(2) in acetate buffer results in rapid modification of the heme group and loss of catalytic activity. Mass spectrometry and NMR indicate that an acetoxy group is covalently bound to the delta-meso-carbon in the modified heme. A heme with a hydroxyl group on the 8-methyl is also formed as a minor product. These reactions do not occur if protein-free heme and H(2)O(2) are co-incubated in acetate buffer, if the HRP reaction is carried out at pH 7, in the absence of H(2)O(2), or if citrate rather than acetate buffer is used. A similar heme modification is observed in incubations with n-caproic and phenylacetic acids. A mechanism involving oxidation of the carboxyl group to a carboxylic radical followed by addition to the delta-meso-position is proposed. This demonstration of the oxidation of a carboxylic acid solidifies the proposal that a carboxylic radical mediates the normal covalent attachment of the heme to the protein in the mammalian peroxidases and CYP4 family of P450 enzymes. The hemoprotein-mediated oxidation of carboxylic acids, ubiquitous natural constituents, may play other roles in biology.
Collapse
Affiliation(s)
- Liusheng Huang
- Contribution from the Department of Pharmaceutical Chemistry, University of California, 600 16th Street, San Francisco, CA 94143-2280, USA
| | | | | |
Collapse
|
46
|
Abstract
The mammalian peroxidases, including myeloperoxidase and lactoperoxidase, bind their prosthetic heme covalently through ester bonds to two of the heme methyl groups. These bonds are autocatalytically formed. No other peroxidase is known to form such bonds. To determine whether features other than an appropriately placed carboxylic acid residue are important for covalent heme binding, we have introduced aspartate and/or glutamic acid residues into horseradish peroxidase, a plant enzyme that exhibits essentially no sequence identity with the mammalian peroxidases. Based on superposition of the horseradish peroxidase and myeloperoxidase structures, the mutated residues were Leu(37), Phe(41), Gly(69), and Ser(73). The F41E mutant was isolated with no covalently bound heme, but the heme was completely covalently bound upon incubation with H(2)O(2). As predicted, the modified heme released from the protein was 3-hydroxymethylheme. The S73E mutant did not covalently bind its heme but oxidized it to the 8-hydroxymethyl derivative. The hydroxyl group in this modified heme derived from the medium. The other mutations gave unstable proteins. The rate of compound I formation for the F41E mutant was 100 times faster after covalent bond formation, but the reduction of compound I to compound II was similar with and without the covalent bond. The results clearly establish that an appropriately situated carboxylic acid group is sufficient for covalent heme attachment, strengthen the proposed mechanism, and suggest that covalent heme attachment in the mammalian peroxidases relates to peroxidase biology or stability rather than to intrinsic catalytic properties.
Collapse
Affiliation(s)
- Christophe Colas
- Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143-2280, USA
| | | |
Collapse
|
47
|
Affiliation(s)
- Christophe Colas
- Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, California 94143-0446, USA
| | | |
Collapse
|
48
|
Venturini M, Lezaun A, Abos T, Fraj J, Monzón S, Colas C, Duce F. Immediate hypersensitivity due to pseudoephedrine. Allergy 2002. [DOI: 10.1046/j.0105-4538.2001.00001.x-i11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
49
|
Abstract
The heme in lactoperoxidase is attached to the protein by ester bonds between the heme 1- and 5-methyl groups and Glu-375 and Asp-275, respectively. To investigate the cross-linking process, we have examined the D225E, E375D, and D225E/E375D mutants of bovine lactoperoxidase. The heme in the E375D mutant is only partially covalently bound, but exposure to H(2)O(2) results in complete covalent binding and a fully active protein. Digestion of this mutant shows that the heme is primarily bound through its 5-methyl group. Excess H(2)O(2) increases the proportion of the doubly linked species without augmenting enzyme activity. The D225E mutant has little covalently bound heme and a much lower activity, neither of which are significantly increased by the addition of heme and H(2)O(2). The heme is linked to this protein through a single bond to the 1-methyl group. The D225E/E375D mutant has no covalently bound heme and no activity. A small amount of iron 1-hydroxymethylprotoporphyrin IX is obtained from the wild-type enzyme along with the predominant dihydroxylated derivative. The results establish that a single covalent link suffices to achieve maximum catalytic activity and suggest that the 5-hydroxymethyl bond may form before the 1-hydroxymethyl bond.
Collapse
Affiliation(s)
- Christophe Colas
- Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, CA 94143-0446, USA
| | | | | |
Collapse
|
50
|
Venturini M, Lezaun A, Abos T, Fraj J, Monzón S, Colas C, Duce F. Immediate hypersensitivity due to pseudoephedrine. Allergy 2002; 57:52-3. [PMID: 11991291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Affiliation(s)
- M Venturini
- Hospital Clínico Universitario, Lozano Blesa, Servicio de alergologia, Zaragoza, Spain
| | | | | | | | | | | | | |
Collapse
|